Krystal Biotech, Inc. operates as a biotechnology company, which engages in developing and commercializing pharmaceutical products. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 275 full-time employees. The company went IPO on 2017-09-20. The firm is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.
Follow-Up Questions
Krystal Biotech Inc (KRYS)의 PER은 얼마입니까?
Krystal Biotech Inc의 PER은 50.1119입니다
Krystal Biotech Inc의 CEO는 누구입니까?
Mr. Krish Krishnan은 2016부터 회사에 합류한 Krystal Biotech Inc의 Chairman of the Board입니다.
KRYS 주식의 가격 성능은 어떻습니까?
KRYS의 현재 가격은 $160.61이며, 전 거래일에 increased 0% 하였습니다.
Krystal Biotech Inc의 주요 사업 주제나 업종은 무엇입니까?
Krystal Biotech Inc은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
Krystal Biotech Inc의 시가총액은 얼마입니까?
Krystal Biotech Inc의 현재 시가총액은 $4.6B입니다
Krystal Biotech Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 13명의 분석가가 Krystal Biotech Inc에 대한 분석 평가를 실시했으며, 이는 6명의 강력한 매수, 10명의 매수, 2명의 보유, 0명의 매도, 그리고 6명의 강력한 매도를 포함합니다
